Sign in6 stories
Cash and financial assets fell to €21.4 million as of June 30, 2026, but the company points to a post-period Sobi deal and share placement to fund operations into 2028.
SEC filing
Sobi partnership closed and TELLOMAK-3 is starting as Innate reports €21.4 million in cash and a runway extended to the end of Q1 2028.
SEC filing (2)
The company announced a call and webcast on August 14, 2026 featuring its CEO, COO, CFO, and IR head.
SEC filing
Sobi will pay $75 million upfront and could owe up to $505 million more as Innate begins a Phase 3 trial toward accelerated approval in Sézary syndrome.
SEC filing
The company's chief medical officer will speak on changing treatments in bladder cancer at the BTIG Virtual Biotechnology Conference on July 28, 2026.
SEC filing
The company enrolled 76 patients in the dose-escalation portion of the trial, with preliminary data expected by year-end 2026.
SEC filing